HK1234053A1 - P-toluenesulfonate for mek kinase inhibitor, and crystal form thereof and preparation method therefor - Google Patents

Description

A kind of tosilate of MEK kinase inhibitors, its crystal form and preparation method Technical field

Crystallized the present invention relates to a kind of tosilate of MEK kinase inhibitors and its I types, tosilate and its I the types crystallization of particularly 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamides.

Background technology

Melanoma is one of clinically relatively conventional malignant tumour, is also one of fastest-rising malignant tumour of the incidence of disease, annual growth is 3-5%, the annual melanoma new cases 199627 in the whole world, and dead number of cases is 46327.Melanoma is relatively low in China's incidence of disease, but is doubled and redoubled in recent years, and 2000 annual morbidities statistics is only 0.2/10 ten thousand, the incidence of disease of 2005-2007 China about 1/,100,000, the annual people of new cases about 20,000, therefore, melanoma have become one of serious disease for jeopardizing our people's health.

Current China is still in the junior stage to the drug research for treating this disease, the medicine Wei Luofeini pieces (Vemurafenib) of the same therapeutic scheme as melanoma and her monoclonal antibody (Ipilimumab, Ipilimumab is a kind of monoclonal antibody), the two medicines are while working, also other disease of skin such as dermoid cancer etc. can be caused, therefore, the medicine of effective treatment melanoma is found, tool is of great significance.

From the result of clinic feedback, MEK kinase inhibitors are to " king of cancer " --- and advanced melanoma has excellent curative effect.Therefore, MEK kinase inhibitors turn into the popular anticancer target spot that each major company falls over each other research and development.

The PCT/CN2014/085976 of the applicant provides a kind of MEK kinase inhibitors being shown below, its chemical entitled 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamides, it has been found that the compound has very strong inhibitory activity to MEK kinases, it is expected to be developed into new melanoma medicine, new therapeutic choice is provided for melanoma patients.

Those skilled in the art will know that, the compound of free alkali form due to its specific defect tend not to directly it is medicinal, most medicines need to provide the reactive compound of other forms to improve these defects, and it is a kind of conventional method that the compound of free alkali form is converted into its officinal salt.In addition, the crystalline structure of medicinal active component often has influence on the chemical stability of the medicine, the difference of crystallization condition and condition of storage is likely to result in the change of the crystalline structure of compound, sometimes can also be along with the crystal formation for producing other forms.In general, unformed drug products do not have well-regulated crystalline structure, often with other defects, such as product stability is poor, and crystallization is thinner, and it is more difficult to filter, easily caking, poor fluidity etc..Therefore, it is necessary to improve each side's surface properties of above-mentioned product, it would be desirable to which it is higher and possess the stable novel crystal forms of good chemical that crystal form purity is found in further investigation.

The content of the invention

The invention provides 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamides tosilate (as shown in formula (I)).

Compound shown in formula (I) can be obtained by p-methyl benzenesulfonic acid and 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamides.

Compound phase shown in formula (I) is for 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyls -1, for 6- dihydropyridine -3- formamides, its solubility and biology Availability is greatly improved, and is more suitable for medicinal.

The series of crystallization product that compound shown in formula (I) is obtained under different crystallization conditions, X- diffraction and DSC detections have been carried out to gained crystallized product, it was found that compound shown in formula (I) is under specific crystallization condition of the invention, a kind of crystal formation having good stability can be obtained, we are called the crystallization of I types.The DSC collection of illustrative plates of I types crystallization in the application, which is shown in 237 DEG C, nearby has melting endothermic peak, X-ray powder diffraction collection is as shown in Figure 1, radiated using Cu-Ka, the X-ray powder diffraction collection represented with 2 θ angles and interplanar distance (d values), wherein in about 10.18 (8.68), 11.51 (7.68), 12.34 (7.17), 12.97 (6.82), 13.72 (6.45), 14.83 (5.97), 15.76 (5.62), 17.13 (5.17), 17.59 (5.04), 17.92 (4.95), 18.50 (4.79), 19.72 (4.50), 20.03 (4.43), 20.42 (4.35), 21.04 (4.22), 21.51 (4.13), 21.88 (4.06), 23.15 (3.84), 24.14 (3.68), 24.53 (3.63), 24.77 (3.59), nearby there is characteristic peak 25.88 (3.44) and 26.37 (3.38).

Present invention also offers the method that the I types for preparing 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamide tosilate are crystallized.This method comprises the following steps：

(1) by p-methyl benzenesulfonic acid and 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyls -1,6- dihydropyridine -3- formamides, or the one or more for being less than or equal to compound shown in any crystal formation or unformed formula (I) in 3 alcohols, ketone, nitrile, ethers selected from carbon number in organic solvent or the in the mixed solvent crystallization of organic solvent and water, the organic solvent；

(2) filtering for crystallizing and wash, dry.

In a preferred embodiment of the present invention, in step (1), organic solvent is preferably methanol, ethanol, isopropanol, and the mixed solvent of organic solvent and water is preferably methanol/water, ethanol/water, isopropanol/water, acetonitrile/water, acetone/water, tetrahydrofuran/water.

Further, most preferred single solvent is isopropanol.

In one embodiment of the invention, mixed solvent preferably is acetone/water, and the two ratio is not particularly limited, in a preferred embodiment of the present invention, and the two volume ratio is 9：1.

The method of recrystallization is not particularly limited, and can be carried out with common recrystallization operation method.For example, slowly cooling crystallization after can in a solvent being dissolved by heating with compound shown in raw material formula (I), after the completion of crystallization, through filtration drying, you can obtain required crystallization.Specifically, the crystalline solid of institute's leaching generally under reduced pressure, at 30~100 DEG C or so, preferably 40~ It is dried in vacuo under 60 DEG C of heating condition, the effect of recrystallization solvent is removed with regard to that can reach.

Determined by differential scanning calorimeter (DSC), X- diffracting spectrums, crystal formation research has been carried out to compound crystalline solid shown in obtained formula (I), while the dissolvent residual crystallized to gained is detected.

The crystallization of compound I types is not contained or the only residual solvent containing lower content shown in formula (I) prepared by the method according to the present invention, meet the limitation requirement about medical product residual solvent as defined in NF, thus the crystallization of the present invention can use preferably as medicating active ingredients.

Research has shown that, the crystallization of compound I types shown in formula (I) prepared by the present invention has good stability under conditions of high temperature, high humidity, and grinding, pressure and it is heated etc. under the conditions of, stability of crystal form is good, it disclosure satisfy that the medicinal requirements of production and transport storage, stable processing technique repeats controllable, can adapt in industrialized production.

Brief description of the drawings

Fig. 1 is the X-ray powder diffraction collection of the crystallization of compound I types shown in formula (I).

Fig. 2 is the DSC spectrograms of the crystallization of compound I types shown in formula (I).

Embodiment

The present invention is explained in greater detail below with reference to embodiment, embodiments of the invention are merely to illustrate technical scheme, and non-limiting the spirit and scope of the invention.

Experiment tester used

1st, DSC is composed

INSTRUMENT MODEL：Mettler Toledo DSC 1 Stare^e System

Purge gass：Nitrogen

Heating rate：10.0℃/min

Temperature range：40-300℃

2nd, x-ray diffraction pattern

INSTRUMENT MODEL：Bruker D8Focus X-ray powder diffraction instrument

Ray：Monochromatic Cu-K alpha rays (λ=1.5406)

Scan mode：The θ of θ/2, scanning range：2-40°

Voltage：40KV, electric current：40mA

Embodiment 1 (preparation of 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamides)

The first step

1- (the fluoro- 4- iodophenyls of 2-) urea

By the fluoro- 4- Iodoanilines 1a (50.80g of 2-, 214mmol) it is dissolved in 254mL chloroforms, triethylamine (60mL, 429mmol) is added, 0 DEG C is cooled to, add N, N'- carbonyl dimidazoles (69.50g, 429mmol), stirring reaction 15 minutes, it is warmed to room temperature, stirring reaction 4 hours.It is cooled to 0 DEG C, add 254mL ammoniacal liquor, filtering, filter cake uses water (50mL × 2), chloroform (20mL × 2), ethyl acetate washing (50mL × 2) successively, drying, crude title product 1- (the fluoro- 4- iodophenyls of 2-) urea 1b (53g, white solid) is obtained, product is not purified directly to carry out next step reaction.

MS m/z(ESI):281.0 [M+1]

Second step

2- cyano group-N- ((the fluoro- 4- iodophenyls of 2-) carbamoyl) acetamide

By crude product 1- (the fluoro- 4- iodophenyls of 2-) urea 1b (113g, 404mmol) it is dissolved in 450mL N, in dinethylformamide, 2- cyanoacetic acids (41g, 488mmol) are added, 0 DEG C is cooled to, add mesyl chloride (55.44g, 484mmol), it is warmed to room temperature, stirring reaction 2 hours.Add 780mL water and isopropanol (V:V=1:2) mixed solution, is stirred for 1 hour.Filtering; filter cake uses water (200mL × 2) successively; ethyl acetate washs (50mL); drying; obtain crude title product 2- cyano group-N- ((the fluoro- 4- iodophenyls of 2-) carbamoyl) acetamide 1c (143g; white solid), product is not purified directly to carry out next step reaction.

MS m/z(ESI):345.9[M-1]

3rd step

6- amino -1- (the fluoro- 4- iodophenyls of 2-) pyrimidine -2,4 (1H, 3H)-diketone

By crude product 2- cyano group-N- ((the fluoro- 4- iodophenyls of 2-) carbamoyl) acetamide 1c (156g; 430mmol) it is dissolved in 628mL water, adds 2M sodium hydroxide solutions (22.6mL, 42mmol); it is heated to 85 DEG C, stirring reaction 1 hour.It is cooled to 0 DEG C, it is 3 that 2M hydrochloric acid, which is added dropwise, to reaction solution pH, adds 300mL isopropanols, filtering, filter cake uses water (200mL × 2) successively, isopropanol washs (100mL × 3), drying, obtains crude title product 6- amino -1- (the fluoro- 4- iodophenyls of 2-) pyrimidine -2,4 (1H, 3H)-diketone 1d (128g, white solid), product is not purified directly to carry out next step reaction.

MS m/z(ESI):348.0[M+1]

4th step

(E)-N'- (3- (the fluoro- 4- iodophenyls of 2-) -2,6- dicarbapentaborane -1,2,3,6- tetrahydropyrimidine -4- bases)-N, N- dimethyl carbonamidines

By crude product 6- amino -1- (the fluoro- 4- iodophenyls of 2-) pyrimidine -2,4 (1H, 3H)-diketone 1d (128g, 368.80mmol) it is dissolved in 250mL N, in dinethylformamide, DMF dimethylacetal (124mL is added, 935mmol), stirring reaction 4.5 hours.Add 720mL water and isopropanol (V:V=5:1) mixed solution, is stirred for 1 hour.Filtering, filter cake uses water (200mL × 2), isopropanol washing (50mL × 2), drying successively, obtain crude title product (E)-N'- (3- (the fluoro- 4- iodophenyls of 2-) -2,6- dicarbapentaborane -1,2,3,6- tetrahydropyrimidine -4- bases)-N, N- dimethyl carbonamidines 1e (132g, white solid), product is not purified directly to carry out next step reaction.

MS m/z(ESI):403.0[M+1]

5th step

(E)-N'- (3- (the fluoro- 4- iodophenyls of 2-) -1- (4- methoxy-benzyls) -2,6- dicarbapentaborane -1,2,3,6- tetrahydropyrimidine -4- bases)-N, N- dimethyl carbonamidines

Crude product (E)-N'- (3- (the fluoro- 4- iodophenyls of 2-) -2,6- dicarbapentaborane -1,2,3,6- tetrahydropyrimidine -4- bases)-N, N- dimethyl carbonamidine 1e (20g, 50mmol) is dissolved in 150mL N, N- dimethyl formyls In amine, 1,8- diazabicyclos [5.4.0] 11 carbon -7- alkene (22.4mL, 150mmol) and 4- methoxyl groups benzyl chloride (14.1mL, 104.30mmol) are added, 75 DEG C, stirring reaction 3 hours are warming up to.Room temperature is cooled to, 675mL water and isopropanol (V is added:V=2:1) mixed solution, is stirred for 1 hour.Filtering, filter cake uses water (200mL × 2), isopropanol washing (50mL × 2), drying successively, obtain crude title product (E)-N'- (3- (the fluoro- 4- iodophenyls of 2-) -1- (4- methoxy-benzyls) -2,6- dicarbapentaborane -1,2,3,6- tetrahydropyrimidine -4- bases)-N, N- dimethyl carbonamidines 1f (35g, white solid), product is not purified directly to carry out next step reaction.

MS m/z(ESI):523.0[M+1]

6th step

1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -6- (methylamino) pyrimidine -2,4 (1H, 3H)-diketone

Sodium borohydride (3.80g, 100mmol) is dissolved in 210mL ethanol and the tert-butyl alcohol (V:V=1:2) in mixed solution, add crude product (E)-N'- (3- (the fluoro- 4- iodophenyls of 2-) -1- (4- methoxy-benzyls) -2,6- dicarbapentaborane -1,2,3,6- tetrahydropyrimidine -4- bases)-N, N- dimethyl carbonamidine 1f (35g, 67mmol), 65 DEG C, stirring reaction 1 hour are warming up to.It is cooled to 0 DEG C, 175mL water is added, the citric acids of 140mL 10% are added, filtered, filter cake uses water (200mL × 2) successively, isopropanol washs (50mL × 2), drying, obtains crude title product 1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -6- (methylamino) pyrimidine -2,4 (1H, 3H)-diketone 1g (33g, white solid), product is not purified directly to carry out next step reaction.

MS m/z(ESI):482.0[M+1]

7th step

1- (the fluoro- 4- iodophenyls of 2-) -5- hydroxyls -3- (4- methoxy-benzyls) -8- picolines simultaneously [2,3-d] pyrimidine -2,4,7 (1H, 3H, 8H)-triketone

By crude product 1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -6- (methylamino) pyrimidine -2,4 (1H, 3H)-diketone 1g (10.80g, 22.44mmol) with diethyl malonate (21.20g, 157.09mmol) it is dissolved in 100mL phenylates, it is warming up to 230 DEG C, stirring reaction 1 hour.It is cooled to room temperature, reaction solution is concentrated under reduced pressure, with silica gel column chromatography with eluant, eluent system B purify gained residue, obtain title product 1- (the fluoro- 4- iodophenyls of 2-) -5- hydroxyls -3- (4- methoxy-benzyls) -8- picolines simultaneously [2,3-d] pyrimidine -2,4,7 (1H, 3H, 8H)-triketone 1h (8.97g, orange/yellow solid), yield：72.9%.

MS m/z(ESI):550.0[M+1]

8th step

The carbonyl-pyridines of 1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -8- methyl -2,4,7- three simultaneously [2,3-d] pyrimidine -5- base triflates

By 1- (the fluoro- 4- iodophenyls of 2-) -5- hydroxyls -3- (4- methoxy-benzyls) -8- picolines simultaneously [2,3-d] pyrimidine -2,4,7 (1H, 3H, 8H)-triketone 1h (8.97g, 16.33mmol) it is dissolved in 100mL dichloromethane, triethylamine (7.00g, 65.32mmol) is added, 0 DEG C is cooled to, add trifluoromethyl sulfonic acid anhydride (9.21g, 32.66mmol), it is warmed to room temperature, stirring reaction 3 hours.Reaction solution is concentrated under reduced pressure, with silica gel column chromatography with eluant, eluent system B purify gained residue, obtain title product 1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -8- methyl -2,4, the carbonyl-pyridines of 7- tri- simultaneously [2,3-d] pyrimidine -5- base triflates 1j (4.13g, yellow solid), yield：37.1%.

MS m/z(ESI):682.0[M+1]

9th step

5- (6- picoline -3- bases epoxide) -1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -8- picolines simultaneously [2,3-d] pyrimidine -2,4,7 (1H, 3H, 8H)-triketone

By 6- methyl -3- Hydroxy-pyridines (26mg, 0.24mmol) it is dissolved in 5mL tetrahydrofurans, adds sodium hydride (12mg, 0.30mmol), stirring reaction 2 hours, add 1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -8- methyl -2,4, the carbonyl-pyridines of 7- tri- simultaneously [2,3-d] pyrimidine -5- base triflate 1j (136mg, 0.20mmol), 60 DEG C, stirring reaction 1 hour are warming up to.Reaction solution is concentrated under reduced pressure, obtain crude title product 5- (6- picoline -3- bases epoxide) -1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -8- picolines simultaneously [2,3-d] pyrimidine -2,4,7 (1H, 3H, 8H)-triketone 31a (128mg, light yellow liquid), product is not purified directly to carry out next step reaction.

MS m/z(ESI):641.1[M+1]

Tenth step

4- (6- picoline -3- bases epoxide) -2- (the fluoro- 4- iodoanilinos of 2-)-N- (4- methoxy-benzyls) -1- methyl -6- carbonyl -1,6- dihydropyridine -3- formamides

By crude product 5- (6- picoline -3- bases epoxide) -1- (the fluoro- 4- iodophenyls of 2-) -3- (4- methoxy-benzyls) -8- picolines simultaneously [2,3-d] pyrimidine -2,4,7 (1H, 3H, 8H)-triketone 1k128mg, 0.20mmol) it is dissolved in 6mL tetrahydrofurans and water (V:V=4:1) in mixed solution, lithium hydroxide (168mg, 4mmol) is added, 40 DEG C, stirring reaction 1 hour are warming up to.50mL ethyl acetate is added, organic phase is washed (30mL × 3) with 1M sodium hydroxide solutions, anhydrous sodium sulfate is done It is dry, filtering, filtrate decompression is concentrated, obtain crude title product 4- (6- picoline -3- bases epoxide) -2- (the fluoro- 4- iodoanilinos of 2-)-N- (4- methoxy-benzyls) -1- methyl -6- carbonyls -1,6- dihydropyridine -3- formamide 1l (123mg, brown oil), product is not purified directly to carry out next step reaction.

MS m/z(ESI):615.0[M+1]

11st step

4- (6- picoline -3- bases epoxide) -2- (the fluoro- 4- iodoanilinos of 2-) -1- methyl -6- carbonyl -1,6- dihydropyridine -3- formamides

By crude product 4- (6- picoline -3- bases epoxide) -2- (the fluoro- 4- iodoanilinos of 2-)-N- (4- methoxy-benzyls) -1- methyl -6- carbonyls -1,6- dihydropyridine -3- formamide 1l (123mg, 0.20mmol) it is dissolved in 5mL methyl phenyl ethers anisoles, add aluminium chloride (133mg, 1mmol), it is warming up to 120 DEG C, stirring reaction 4 hours.Add 50mL ethyl acetate and 15mL water, organic phase is washed with water (25mL × 3), anhydrous sodium sulfate drying, filtering, filtrate decompression concentration, with preparative separation method purify obtained by residue, obtain title product 2- (the fluoro- 4- iodoanilinos of 2-) -1- methyl -4- (6- picoline -3- bases epoxide) -6- carbonyls -1,6- dihydropyridine -3- formamides 1 (30mg, light tan solid), yield：30.3%.

MS m/z(ESI):495.0[M+1]

¹H NMR(400MHz,DMSO-d₆):δ9.78(s,1H),8.38-8.44(m,1H),7.57-7.75(m,4H),7.35-7.49(m,2H),6.65(t,1H),5.09(s,1H),3.15(s,3H),2.51(s,3H).

Embodiment 2

By (1g, 2.02mmol) 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyls -1,6- dihydropyridine -3- formamides, p-methyl benzenesulfonic acid (0.39g, 2.27mmol) added with isopropanol (20.41g) in reaction bulb, 2~2.5h of back flow reaction.Stop heating, continue to stir 12~14h, stop reaction, filtering, filter cake is washed with isopropanol (100g), and 40~45 DEG C are dried under reduced pressure 6~7h, obtain solid 1.10g, yield：81.6%.The X-ray diffraction spectrogram of the crystallized sample is shown in Fig. 1.The crystallization is in about 10.18 (8.68), 11.51 (7.68), 12.34 (7.17), 12.97 (6.82), 13.72 (6.45), 14.83 (5.97), 15.76 (5.62), 17.13 (5.17), 17.59 (5.04), 17.92 (4.95), 18.50 (4.79), 19.72 (4.50), 20.03 (4.43), 20.42 (4.35), 21.04 (4.22), 21.51 (4.13), 21.88 (4.06), 23.15 (3.84), 24.14 (3.68), 24.53 (3.63), 24.77 (3.59), 25.88 (3.44) There is characteristic peak with 26.37 (3.38) places.DSC spectrograms are shown in Fig. 2, have sharp melting endothermic peak near 237 DEG C, we are defined as I crystal.

Embodiment 3

Take compound (being prepared by embodiment 2) shown in (1.0g, 1.50mmol) formula (I) to be added in 50ml single port bottles, add 28ml methanol, dissolve by heating, it is cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.30g, yield 30.0%.Its X- diffraction and DSC collection of illustrative plates are compared through research, and it is I crystal to determine product.

Embodiment 4

Take compound (being prepared by embodiment 2) shown in (1.0g, 1.50mmol) formula (I) to be added in 250ml single port bottles, add 100ml ethanol, dissolve by heating, it is cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.40g, yield 40.0%.Its X- diffraction and DSC collection of illustrative plates are compared through research, and it is I crystal to determine product.

Embodiment 5

Take compound (being prepared by embodiment 2) shown in (1.0g, 1.50mmol) formula (I) to be added in 25ml single port bottles, add the methanol of 6ml 95%, dissolve by heating, it is cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.48g, yield 48.0%.Its X- diffraction and DSC collection of illustrative plates are compared through research, and it is I crystal to determine product.

Embodiment 6

Take (1.0g, 1.50mmol) compound (being prepared by embodiment 2) shown in formula (I) is added in 50ml single port bottles, add the ethanol of 24ml 95%, dissolve by heating, be cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.50g, yield 50.0%.Its X- diffraction and DSC collection of illustrative plates are compared through research, and it is I crystal to determine product.

Embodiment 7

Take (1.0g, 1.50mmol) compound (being prepared by embodiment 2) shown in formula (I) is added in 50ml single port bottles, add the isopropanols of 18ml 90%, dissolve by heating, be cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.48g, yield 48.0%.Its X- diffraction and DSC collection of illustrative plates are compared through research, and it is I crystal to determine product.

Embodiment 8

Take (1.0g, 1.50mmol) compound (being prepared by embodiment 2) shown in formula (I) is added in 50ml single port bottles, add the acetonitriles of 12ml 90%, dissolve by heating, be cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.46g, yield 46.0%.Its X- diffraction Compared with DSC collection of illustrative plates through research, it is I crystal to determine product.

Embodiment 9

Take (1.0g, 1.50mmol) compound (being prepared by embodiment 2) shown in formula (I) is added in 50ml single port bottles, add the tetrahydrofurans of 28ml 95%, dissolve by heating, be cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.70g, yield 70.0%.Its X- diffraction and DSC collection of illustrative plates are compared through research, and it is I crystal to determine product.

Embodiment 10

Take (1.0g, 1.50mmol) compound (being prepared by embodiment 2) shown in formula (I) is added in 50ml single port bottles, add the acetone of 20ml 90%, dissolve by heating, be cooled to room temperature, stirring and crystallizing, suction filtration, vacuum drying, obtains solid 0.54g, yield 54.0%.Its X- diffraction and DSC collection of illustrative plates are compared through research, and it is I crystal to determine product.

Embodiment 11

Take compound (being prepared by embodiment 2) shown in (1.0g, 1.50mmol) formula (I) to be added in 50ml single port bottles, add the acetone of 20ml 90%, it is heated to reflux dissolved clarification, it is cooled to addition 40ml acetone, stirring and crystallizing in room temperature, cooling procedure.Next day, suction filtration, dry white solid 710mg, yield is 71.0%.

Embodiment 12

By the I type crystallized products sample of the gained of embodiment 2, opening divides placement respectively, investigates in illumination, heats (40 DEG C, 60 DEG C), the stability of sample under the conditions of high humidity (RH75%, RH90%).It is 5 days and 10 days to investigate sample time, and HPLC detections purity is shown in Table 1.

The stability of compound I type crystallized samples shown in the formula of table 1. (I)

Study on the stability result shows, compound I types crystallized sample shown in formula (I) is under conditions of opening is placed, through the stability under illumination, high temperature and super-humid conditions it was found that, illumination, high humidity and high temperature influence little to the quality of product, illustrate that it has preferable stability.

Embodiment 13

The crystallization of compound I types shown in formula (I) it will be ground, add as made from the method for embodiment 2 Heat and compressing tablet process, result of study show stable crystal form, and detailed experimental data is referring to table 2 below.

The special stability study of compound I crystal shown in the formula of table 2. (I)

Claims (7)

1. 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamide tosilate shown in formula (I),
2. 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyls -1 shown in formula (I) according to claim 1, the I types crystallization of 6- dihydropyridine -3- formamide tosilate, it is characterised in that：Radiated using Cu-Ka, obtain the X-ray powder diffraction collection represented with 2 θ angles and interplanar distance, the crystallization has X-ray powder diffraction collection as shown in Figure 1, wherein in about 10.18 (8.68), 11.51 (7.68), 12.34 (7.17), 12.97 (6.82), 13.72 (6.45), 14.83 (5.97), 15.76 (5.62), 17.13 (5.17), 17.59 (5.04), 17.92 (4.95), 18.50 (4.79), 19.72 (4.50), 20.03 (4.43), 20.42 (4.35), 21.04 (4.22), 21.51 (4.13), 21.88 (4.06), 23.15 (3.84), 24.14 (3.68), 24.53 (3.63), 24.77 (3.59), nearby there is characteristic peak 25.88 (3.44) and 26.37 (3.38).
3. One kind prepares 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyls -1 shown in formula according to claim 1 (I), the method of 6- dihydropyridine -3- formamide tosilate, the step of including by p-methyl benzenesulfonic acid and 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamides.
4. One kind prepares 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- first shown in formula according to claim 1 (I) The method of the I types crystallization of acid amides tosilate, methods described comprises the steps：

   1) by p-methyl benzenesulfonic acid and 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyls -1, 6- dihydropyridine -3- formamides, or by 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyls -1 shown in any crystal formation or unformed formula (I), 6- dihydropyridines -3- formamides tosilate is in organic solvent or the in the mixed solvent crystallization of organic solvent and water, the organic solvent is selected from the alcohols that carbon number is less than or equal to 3, ketone, nitrile, the one or more of ethers；

   2) filtering for crystallizing and wash, dry.
5. Method according to claim 4, it is characterised in that in step 1) described in organic solvent be selected from methanol, ethanol, the one or more of isopropanol；The mixed solvent of organic solvent and water is selected from methanol/water, ethanol/water, isopropanol/water, acetonitrile/water, acetone/water, tetrahydrofuran/water；It is preferred that single solvent is isopropanol, mixed solvent is acetone/water.
6. A kind of pharmaceutical composition, it contains 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1, the 6- dihydropyridine -3- formamides tosilate or the crystallization of its I type and pharmaceutically acceptable carrier shown in formula according to claim 1 (I).
7. Purposes of the pharmaceutical composition described in the crystallization of I types or claim 6 in the medicine for preparing the treatment disease relevant with MEK kinase inhibitors described in 2- ((the fluoro- 4- iodophenyls of 2-) amino) -1- methyl -4- ((6- picoline -3- bases) epoxide) -6- carbonyl -1,6- dihydropyridine -3- formamides tosilate, claim 2 shown in formula (I) according to claim 1；The disease is preferably tumour, more preferably melanoma.